All In Biotech

Drug Trial Radar · NCT01436162

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

The SPD489-323 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant

Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,105

Actual

Start

Oct 19, 2011

Primary completion

Dec 10, 2013

Study completion Dec 10, 2013

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 19, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions: * How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? * Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant? * How much SPD489 should be given to patients with depression who are also taking an antidepressant? * How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?

Conditions

  • Major Depressive Disorder

Interventions

  • Antidepressant + SPD489 (Lisdexamfetamine dimesylate )Drug

    Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks

  • Antidepressant + PlaceboDrug

    Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 WeeksTime frame: 8 weeks

Locations

101 sites in 11 countries. Site status is shown where the registry gives one.

  • ResearchOne, Inc.

    Scottsdale, Arizona

  • K&S Professional Research Services, LLC

    Little Rock, Arkansas

  • ATP Clinical Research, Inc.

    Costa Mesa, California

  • Diligent Clinical Trials

    Downey, California

  • Synergy Clinical Reserach Center of Escondido

    Escondido, California

  • Pacific Research Partners, LLC

    Oakland, California

  • Anderson Clinical Research

    Redlands, California

  • BreakThrough Clinical Trials, LLC

    San Bernardino, California

  • MCB Clinical Research Centers

    Colorado Springs, Colorado

  • Florida Clinical Research Center, LLC

    Bradenton, Florida

  • Scientific Clinical Research, Inc.

    North Miami, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Comprehensive NeuroScience, Inc.

    St. Petersburg, Florida

  • Janus Center for Psychiatric Research

    West Palm Beach, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • Atlanta Institute of Medicine & Research

    Atlanta, Georgia

  • Pedia Research

    Newburgh, Indiana

  • Heartland Research Associates

    Wichita, Kansas

  • Louisiana Clinical Research, LLC

    Shreveport, Louisiana

  • Comprehensive Psychiatric Associates

    Gladstone, Missouri

  • The Center for Pharmaceutical Research

    Kansas City, Missouri

  • Mercy Health Research

    St Louis, Missouri

  • Bio Behavioral Health

    Toms River, New Jersey

  • Brooklyn Medical Institute

    Brooklyn, New York

  • Medical & Behavioral Health Research, PC

    New York, New York

  • Midwest Clinical Research Center

    Dayton, Ohio

  • North Star Medical Research, LLC

    Middleburg Heights, Ohio

  • Sooner Clinical Research

    Oklahoma City, Oklahoma

  • Lehigh Center for Clinical Research

    Allentown, Pennsylvania

  • Belmont Center for Comprehensive Treatment

    Philadelphia, Pennsylvania

  • Medical University South Carolina Anxiety Disorder Program

    North Charleston, South Carolina

  • Psychiatric Consultants, PC

    Franklin, Tennessee

  • Research Strategies of Memphis, LLC

    Memphis, Tennessee

  • KRK Medical Research

    Dallas, Texas

  • Future Search Trials of Dallas, LP

    Dallas, Texas

  • Clinical Trials of Texas, Inc.

    San Antonio, Texas

  • Dr Lieven De Weirdt

    Sint-Niklaas, Belgium

  • Saint Anne s.r.o.

    Brno, Czechia

  • Psychiatricka ambulance

    Brno, Czechia

  • Medicana s.r.o.

    Hořovice, Czechia

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.